Instil Bio Inc

NASDAQ:TIL   10:56:24 AM EDT
+0.02 (+2.98%)
Layoffs, Earnings Announcements

Instil Bio Board Approves An Expansion Of Its Previously Announced Realignment Plan

Published: 02/01/2023 23:38 GMT
Instil Bio Inc (TIL) - On January 30, 2023, Board Approved an Expansion of Its Previously Announced Realignment Plan.
Approved Expansion of Its Realignment Plan Implementing Strategic Prioritization of Co's Preclinical, Clinical Development Programs.
Will Extend Previously Announced U.S. Reduction in Force, Resulting in Team of About 15 in United States to Lead Global Business Operations.
Reduction is Expected to Be Substantially Completed in April 2023.
In Connection With Plan, Company Estimates That It Will Incur Aggregate Restructuring Costs of Up to $3.0 Million.
In Connection With Plan, Expects to Transition Clinical Manufacturing, Trial Operations of Itil-306 to Its Operations in United Kingdom.
Further Company Coverage: Tilo ((reuters.
Revenue is expected to be $0.33 Million
Adjusted EPS is expected to be -$0.42

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.29

More details on our Analysts Page.